Late stage trials of the vaccine being jointy developed by AstraZeneca and the University of Oxford show it to be “highly effective.”
AstraZeneca and the University of Oxford on Monday said their jointly-developed vaccine against the coronavirus has shown “an average efficacy of 70%” in trials.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” AstraZeneca’s chief executive Pascal Soriot said in a statement.
The vaccine can prevent 70% of people from getting the virus and up to 90% if a lower dose is used, according to the biopharmaceutical firm’s data.
British Prime minister Boris Johnson said it was “incredibly exciting news the Oxford vaccine has proved so effective in trials.”
AstraZeneca’s proposed vaccine produced less effective results when compared with others produced by rivals Pfizer/BioNTech and Moderna which have shown to be around 95% effective.
It had two dose regimen:
One showed an effectiveness of 90% when trial participants received a half dose, followed by a full dose at least one month apart. The other dosing regimen showed 62% efficacy when given as two full doses at least one month apart.
The combined analysis from both dosing regimens found average vaccine effectiveness of 70%. No hospitalizations or severe cases of the disease were reported in participants receiving the vaccine.
Nevertheless, the preliminary trial results still represent a fresh breakthrough in the fight against a virus that has killed nearly 1.4 million people, brought global travel to a standstill and devastated the global economy.